

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10599892
Filing Date	2006-10-12
First Named Inventor	Aloke K. Dutta
Art Unit	1626
Examiner Name	Unknown
Attorney Docket Number	WSU 0203 PUSA

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS							Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10599892
Filing Date		2006-10-12
First Named Inventor	Aloke K. Dutta	
Art Unit		1626
Examiner Name	Unknown	
Attorney Docket Number		WSU 0203 PUSA

1	[Pub44.pdf]: Dutta, A.K., Davis, M.C., Reith, M. E. A. Rational Design and synthesis of novel conformationally constrained 2,5-disubstituted cis- and tras-piperidine derivatives exhibiting differential activity for the dopamine transporter. Bioorg. Med. Lett. 2001, 11, 2337-2340.	<input type="checkbox"/>
2	[Pub45.pdf]: Kolhatkar R.B., Ghorai S.K., George C, Reith M. E. A, Dutta A K. Interaction of cis-(6- benzhydryl-piperidin-3-yl)-benzyl-amine analogs with monoamine transporters: Structure Activity Relationship study of structurally constrained 3,6-disubstituted piperidine analogs of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidine-4-ylmethyl]amine. J. Med. Chem. 2003, 46, 2205-2215.	<input type="checkbox"/>
3	[Pub46.pdf]: Zhang S, Reith M E A, Dutta A K. Design, synthesis, and activity of novel cis- and trans-3,6-disubstituted pyran biomimetics of 3,6-disubstituted piperidine as potential ligands for the dopamine transporter. Bioorg. Med. Chem. Lett. 13, 1591-1595, 2003.	<input type="checkbox"/>
4	[Pub47.pdf]: Zhang, S., Zhen, J., Reith, M.E.A., Dutta, A.K., "Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters," Bioorganic Medicinal Chemistry, 2004, 12, 6301-6315.	<input type="checkbox"/>
5	[Pub48.pdf]: J. Langston et al., "MPTP: Current Concepts and Controversies," Clin. Neuropharmac., 1986, 9, 485-507.	<input type="checkbox"/>
6	[Pub49.pdf]: Cookson, "J. Side Effects of Antidepressants," Br. J. Psychiatry, 20, 20-24, 1993	<input type="checkbox"/>
7	[Pub50.pdf]: A.K. Dutta et al., "Positional Importance of the Nitrogen Atom in Novel Piperidine Analogs of GBR 12909: Affinity and Selectivity for the Dopamine Transporter," Med. Chem. Res., 1993, 3, 209-222	<input type="checkbox"/>
8	[Pub51.pdf]: Shoemaker, H., et al., "Naunyn Schmiedebergs Arch. Pharmacol., 1985, 329, 227-235	<input type="checkbox"/>
9	[Pub52.pdf]: Baker Botts, "In Prints - Reach-Through Claims," http://www.bakerbotts.com/news/printpage.asp?pubid=19221417 (2 pgs.)	<input type="checkbox"/>
10	[Pub53.pdf]: Gourley, D.R.H., "Biological Responses to Drugs," Medicinal Chemistry, 3rd Ed., Part I, p. 25	<input type="checkbox"/>
11	[Pub54.pdf]: Zhang, S., et al., "Design, Synthesis, and Preliminary SAR Study of 3- and 6-Side Chain Extended Tetrahydro-Pyran Analogues of cis- and trans-(6-benzhydryl-piperidin-3-yl)-benzylamine," Bioorg. Med. Chem. 14, 3953-3966, 2006	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10599892
Filing Date	2006-10-12
First Named Inventor	Aloke K. Dutta
Art Unit	1626
Examiner Name	Unknown
Attorney Docket Number	WSU 0203 PUSA

12	[Pub37.pdf]: Koch, S., Hemrick-Luecke, S., Thompson, L., Evans, D., Threlkeld, P., Nelson, D., Perry, K., Bymaster, F. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology. 2003, 45, 935-944.	<input type="checkbox"/>
13	[Pub38.pdf]: Nemeroff, C. B. Psychopharmacology of affective disorders in the 21 st century. Biol. Psychiatry. 44, 517-525, 1998.	<input type="checkbox"/>
14	[Pub39.pdf]: Iverson, L. Neurotransmitter transporters: fruitful targets for CNS drug discovery. Mol. Psychiatry. 5, 357-362, 2000.	<input type="checkbox"/>
15	[Pub40.pdf]: Schloss, P., Williams, D. C. The serotonin transporter: a primary target for antidepressant drugs. J. Psychopharmacol. 12, 115-121, 1998.	<input type="checkbox"/>
16	[Pub41.pdf]: Feighner, J. P. Mechanism of action of antidepressant medications. J. Clin. Psychiatry. 60, 4-11, 1999.	<input type="checkbox"/>
17	[Pub42.pdf]: Pinder, R. M., Wieringa, J. H. Third-generation antidepressants. Med. Res. Rev. 13, 259-325, 1993.	<input type="checkbox"/>
18	[Pub43.pdf]: Barbey, J. T., Roose, S. P. SSRI safety in overdose. J. Clin. Psychiatry. 59 Suppl 15:42--8, 1998.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.